Investor Relations Sequenom

Sequenom CMM Opens New CLIA Lab Facility In North Carolina

Wed, 12 Jun 2013 07:00:00 -0400

Jun 12, 2013

SAN DIEGO, June 12, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that its wholly owned subsidiary, the Sequenom Center for Molecular Medicine (Sequenom CMM), has completed the build-out and validation of an additional laboratory location in Raleigh-Durham, NC, and is now processing patient samples commercially. This new laboratory location adds capacity and redundancy to the existing Sequenom CMM laboratory locations in California and Michigan.

With an initial capacity of 100,000 tests per year, the North Carolina facility will primarily support processing of the MaterniT21 PLUS laboratory-developed test (LDT) and will immediately increase Sequenom CMM's total MaterniT21 PLUS testing capacity to over 300,000 test samples per year. This practice-changing prenatal LDT analyzes the relative amount of chromosome 21, 18, and 13, as well as X and Y material in cell-free fetal DNA obtained from a maternal blood sample as early as 10 weeks of pregnancy.

"We are excited about the opening in North Carolina of our third US-based laboratory location. Our investment in establishing this new presence on the East coast will allow us to better meet the needs of health care providers by providing critical additional capacity and geographic back-up needed to address the rapidly growing adoption of our testing services," said William Welch, President and COO, Sequenom, Inc.

The new laboratory location received its Clinical Laboratory Improvement Amendments (CLIA) registration for operation in May of 2013.

The MaterniT21 PLUS LDT is intended for use in pregnant women at increased risk for fetal aneuploidy. Estimates suggest there are about 750,000 pregnancies at high risk for fetal aneuploidy each year in the United States. The MaterniT21 PLUS test is available exclusively through the Sequenom CMM as a testing service provided to physicians. To learn more about the test, please visit www.Sequenomcmm.com.

About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

About Sequenom Center for Molecular Medicine
Sequenom Center for Molecular Medicine (Sequenom CMM^®) is a CAP accredited and CLIA-certified molecular diagnostics reference laboratory currently with three locations dedicated to the development and commercialization of laboratory-developed tests for prenatal and eye conditions and diseases. Utilizing innovative proprietary technologies, Sequenom CMM provides test results that can be used by health care professionals in managing patient care. Testing services are available only upon request by physicians. Sequenom CMM works closely with key opinion leaders and experts in obstetrics, retinal care and genetics. Sequenom CMM scientists use a variety of sophisticated and cutting-edge methodologies in the development and validation of tests. Sequenom CMM is changing the landscape in genetic diagnostics. Visit http://www.sequenomcmm.com for more information on laboratory testing services.

SEQUENOM^®, Sequenom CMM^®, MaterniT21™ and MaterniT21™ PLUS are trademarks of Sequenom, Inc.

Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the Company's expectations regarding the impact, utility and benefits of the North Carolina facility, and the growing adoption of Sequenom CMM's testing services, the Company's commitment to improving healthcare through revolutionary genetic analysis solutions, and Sequenom CMM's dedication to the development and commercialization of laboratory-developed tests for prenatal and eye conditions and diseases and changing the landscape in genetic diagnostics, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market demand for and acceptance and use of technology and tests such as the MaterniT21 PLUS test, reliance upon the collaborative efforts of other parties such as, without limitation, healthcare providers, international distributors and licensees, the Company or third parties obtaining or maintaining regulatory approvals that impact the Company's business, government regulation particularly with respect to diagnostic products and laboratory developed tests, publication processes, the performance of designed product enhancements, the Company's ability to develop and commercialize technologies and products, particularly new technologies such as noninvasive prenatal diagnostics, laboratory developed tests, and genetic analysis platforms, the Company's financial position, the timing and amount of reimbursement that Sequenom CMM receives from payors for its laboratory developed tests, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, litigation involving the Company, and other risks detailed from time to time in the Company's most recently filed Quarterly Report on Form 10-Q, its most recently filed reports on Form 8-K, and its most recently filed Annual Report on Form 10-K, and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

SOURCE Sequenom, Inc.

Sequenom Announces License And Marketing Agreements With Laboratoire Cerba In France

Thu, 30 May 2013 07:00:00 -0400

May 30, 2013

SAN DIEGO and ST OUEN L'AUMONE, France, May 30, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that it, along with its wholly owned subsidiary, Sequenom Center for Molecular Medicine (Sequenom CMM), has entered into technology licensing and marketing agreements with Laboratoire Cerba in France for noninvasive prenatal aneuploidy testing. These agreements will expand access to Sequenom CMM's MaterniT21™ PLUS laboratory-developed test and the technology used in the test to healthcare providers and their patients via Laboratoire Cerba's network in France, Belgium, Luxembourg and portions of the Middle East and Africa.

"This new relationship with Laboratoire Cerba, one of the leading diagnostics service providers in Europe, will enable us to leverage Laboratoire Cerba's strong network of facilities to provide healthcare providers and their patients with access to our innovative noninvasive prenatal testing (NIPT) technology," said William Welch, President and COO, Sequenom, Inc. "We look forward to collaborating with Cerba to continue to build upon the momentum we've seen with the adoption of our testing services worldwide."

Under the terms of the license agreement, Sequenom will license its cell-free fetal nucleic acid technology to Laboratoire Cerba to establish its noninvasive fetal aneuploidy testing service in France. Laboratoire Cerba will also have rights to market its noninvasive testing service in multiple countries, including France, Luxembourg, Belgium, Lebanon, Morocco, Algeria, Tunisia, Libya, Senegal, Ivory Coast, Burkina Faso and Cameroun. Effective immediately, the contract term for the technology license is active through 2018.

"Combining Sequenom CMM's prenatal testing technology with our laboratory testing expertise and network is great news for expectant families in Europe, as we will be able to provide them important information about their pregnancies in an accurate, safe and efficient method," said Sylvie CADO, COO, Laboratoire Cerba. "We believe our markets are anxious for access to NIPT technology, and we are enthusiastic to develop this innovative test in France. This collaboration gives us the opportunity to increase our portfolio in the field of noninvasive prenatal diagnosis. We look forward to a successful and productive relationship with Sequenom and Sequenom CMM."

The MaterniT21 PLUS LDT analyzes the relative amount of 21, 18, 13, as well as X and Y chromosomal material in cell-free DNA. The test is intended for use in pregnant women at increased risk for fetal aneuploidy and can be used as early as 10 weeks' gestation. Estimates suggest there are about 750,000 pregnancies at high risk for fetal aneuploidy each year in the United States. The MaterniT21 PLUS test is available exclusively through the Sequenom CMM as a testing service provided to physicians. To learn more about the test, please visit www.Sequenomcmm.com.

About Sequenom Center for Molecular Medicine
Sequenom Center for Molecular Medicine (Sequenom CMM^®) is a CAP accredited and CLIA-certified molecular diagnostics reference laboratory currently with two locations dedicated to the development and commercialization of laboratory developed tests for prenatal and eye conditions and diseases. Utilizing innovative proprietary technologies, Sequenom CMM provides test results that can be used by health care professionals in managing patient care. Testing services are available only upon request by physicians. Sequenom CMM works closely with key opinion leaders and experts in obstetrics, retinal care and genetics. Sequenom CMM scientists use a variety of sophisticated and cutting-edge methodologies in the development and validation of tests. Sequenom CMM is changing the landscape in genetic diagnostics. Visit http://www.sequenomcmm.com for more information on laboratory testing services.

SEQUENOM^®, MaterniT21™ and MaterniT21™ PLUS are trademarks of Sequenom, Inc. All other trademarks and service marks are the property of their respective owners.

About Laboratoire Cerba
Laboratoire Cerba is a leading European specialized laboratory based in France and ISO 15189 accredited. Since its inception in 1967, it offers private laboratories and public hospitals in more than 35 countries a broad range of specialty testing services, such as molecular biology testing, oncology testing, allergy testing, hormonology testing, infectious disease testing and diagnostic genetic testing and has developed a broadly recognized expertise in innovation for new tests.

It is the founding member of the Cerba European Lab Group, a leading European clinical pathology laboratory, providing routine and specialized clinical laboratory testing services primarily in France, Belgium and Luxembourg, and supporting pharmaceutical and biotechnology companies worldwide in the clinical trial phase of their drug development processes.

Through its Routine Lab and Specialized Testing operations, the Group offers a range of over 2000 routine and specialty clinical tests used by doctors and medical institutions to diagnose, monitor and treat diseases. The Central Lab testing operations, which operated through the BARC subsidiaries, provide safety and efficacy testing services to pharmaceutical companies and contact research organizations worldwide in connection with drug development processes.

For more information concerning CERBA, please consult our web site www.lab-cerba.com

Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding expectations for the development and commercialization of prenatal laboratory testing services in Europe, Africa and the Middle East, including laboratory developed tests for fetal aneuploidies, the duration of and performance, sales and payment expectations under the licensing agreement and marketing agreement, the potential for additional launches in other countries, and Sequenom's commitment to improving healthcare through revolutionary genetic analysis solutions, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with reliance upon the collaborative efforts of Laboratoire Cerba, Sequenom, and Sequenom CMM and those parties' abilities to develop and commercialize new technologies and products, particularly new technologies such as prenatal and other diagnostics and laboratory developed tests, Sequenom's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, ongoing litigation and investigations and other risks detailed from time to time in Sequenom, Inc.'s most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Sequenom, Inc. undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

SOURCE Sequenom, Inc.

Sequenom Announces Participation At The Jefferies Global Healthcare Conference

Tue, 28 May 2013 07:00:00 -0400

May 28, 2013

SAN DIEGO, May 28, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced the Company's participation at the Jefferies 2013 Global Healthcare Conference at the Grand Hyatt in New York, NY on June 3-6, 2013.

Harry F. Hixson, Jr., Ph.D., Chairman and CEO, will present on Tuesday, June 4, 2013, beginning at 11:30 a.m. ET, to provide an overview of and update on the Company. The presentation is expected to last approximately 30 minutes and will be webcast live through the "Investors" section of the Sequenom website at www.sequenom.com. An audio replay will be available for 30 days following the initial presentation webcast.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

SOURCE Sequenom, Inc.

Sequenom, Inc. Reports Financial Results For The First Quarter Of 2013

Thu, 09 May 2013 16:10:00 -0400

158% Year-Over-Year Increase In Total Revenues Led By Continued Growth In Diagnostics Sales Volumes

May 9, 2013

SAN DIEGO, May 9, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today reported revenue of $38.5 million for the first quarter of 2013, an increase of 158% compared to revenue of $14.9 million for the first quarter of 2012. First quarter 2013 revenues from the Sequenom Center for Molecular Medicine (Sequenom CMM) diagnostics services operating segment grew more than 38% as compared to the fourth quarter of 2012.

"The volume of 35,000 MaterniT21™ PLUS tests accessioned in the first quarter shows that Sequenom CMM continued to take advantage of its first mover position in the non-invasive prenatal diagnostic (NIPT) market by increasing its penetration of the NIPT market and maintaining its dominant market share. The recent announcement that Sequenom CMM had accessioned over 100,000 MaterniT21 PLUS test samples since the test was launched in October of 2011 is further evidence of the remarkable success of this testing service," said Harry F. Hixson, Jr., Ph.D., Chairman and CEO of Sequenom. "Furthermore, we are making progress in our negotiations within the payor community, with more than 70 million patients now under coverage who have access to the MaterniT21 PLUS test."

Revenues from the Sequenom CMM diagnostics services operating segment grew to more than $29 million in the first quarter of 2013, up from $4.8 million in the prior year period. As of the first quarter 2013, diagnostic revenue accounted for more than 75% of total revenue, up from 63% in the fourth quarter of 2012.

Revenues from the Sequenom CMM diagnostics services operating segment are recorded primarily on a cash basis. Approximately 35% of diagnostic revenue reported for the first quarter 2013 is attributable to tests performed in the same period. Approximately 65% of the diagnostic revenue reported in the first quarter 2013 is related to payment collected on tests performed in prior periods. First quarter 2013 revenues from the genetic analysis operating segment decreased 7% from the same period in 2012, due to a softening in consumables orders, partially due to timing.

Total cost of revenues increased to $24.5 million for the first quarter of 2013, compared to $10.3 million for the prior year period. Cost of revenues increased primarily due to the significant increase in Sequenom CMM's test volumes and costs to support increased testing capacity, as total tests accessioned increased 250% to more than 44,500 patient samples during the first quarter of 2013. Approximately 35,000 of those patient samples tested during the first quarter were MaterniT21 PLUS test samples, compared to approximately 25,000 in the fourth quarter of 2012, growing 40% sequentially.

Overall gross margin for the first quarter of 2013 was 36% as compared to gross margin of 31% for the first quarter of 2012. This improvement is attributable primarily to the positive contribution from the Sequenom CMM diagnostic services business resulting from higher cash collections during the quarter and improved efficiencies in processing patient samples. Gross margin for the Sequenom CMM diagnostics services business in the first quarter of 2013 was approximately 28%, as compared to a negative gross margin in the first quarter of 2012. Gross margin for the genetic analysis business for the first quarter of 2013 was 63% compared to 66% for the prior year period.

Total operating expenses for the first quarter of 2013 were $41.0 million, as compared to total operating expenses of $28.9 million for the first quarter of 2012, down sequentially from total operating expenses of $42.0 million for the fourth quarter of 2012. Selling and marketing expenses increased to $13.7 million for the first quarter of 2013 from $9.7 million year-over-year, resulting primarily from higher labor costs associated with the expansion of the Sequenom CMM sales force and increased headcount to support commercial operations. Research and development expenses increased to $13.8 million for the first quarter of 2013, as compared to $11.8 million in the first quarter of 2012, related primarily to increased labor and supplies and costs relative to the expansion into the Sequenom CMM North Carolina facilities.

General and administrative expenses for the first quarter of 2013 were $13.5 million, as compared to $7.4 million for the first quarter of 2012, primarily due to increased legal expenses associated with patent litigation, increased collection costs due to the increase in diagnostics revenue and increased headcount to support the Company's operations. Total stock-based compensation expense was $3.1 million for the first quarter of 2013, an increase from $2.9 million in stock-based compensation recorded for the first quarter of 2012.

Net loss for the first quarter of 2013 was $29.4 million, or $0.26 per share, as compared to net loss of $24.4 million, or $0.22 per share, for the same period in 2012. Net cash used in operating activities was $19.7 million for the first quarter of 2013, compared to $23.3 million in the same period in the prior year. The Company also used cash for capital investments of $4.1 million and debt repayments of $1.8 million during the first quarter of 2013. As of March 31, 2013, total cash, cash equivalents, and marketable securities were $151.1 million.

"We are pleased to see sequential improvements in volume, revenue and margin during the quarter, an indication of steady growth and sustained momentum in 2013," said Paul V. Maier, Sequenom's CFO. "As we complete the process of moving our billing and collections processes in-house, we anticipate even greater control in monitoring our payments from payors and improved workflows that will help us improve our collection cycle and reimbursement."

Operational Updates
The Company recently reported that Sequenom CMM had processed 100,000 MaterniT21 PLUS samples since launch of the testing service in October 2011, reflecting the overwhelmingly positive response from the physician community based on the superior attributes of the test and customer support offered by Sequenom CMM. Nearly 60% of maternal-fetal medicine specialists and more than 3,300 OBGYN physicians in the United States have ordered the test since its introduction.

The annualized run rate for the MaterniT21 PLUS test at the end of the first quarter surpassed 140,000 samples. This growth has continued with a record number of samples accessioned in the last week of April and Sequenom CMM expects to exceed 150,000 samples accessioned for all of 2013.

During the first quarter, Sequenom CMM published several key studies that support enhanced performance and clinical utility of both the MaterniT21 PLUS test, and the RetnaGene™ AMD laboratory-developed test for age related macular degeneration (AMD). A publication in PLOS One in March 2013 describes the basis of process enhancements to the MaterniT21 PLUS test, along with equivalence data in a large clinical sample set.

Sequenom CMM also announced that the MaterniT21 PLUS test now reports on the presence of fetal sex chromosomal aneuploidies, in addition to its identification of aneuploidies for chromosomes 21, 18 and 13. Results of a blinded clinical study reporting on detection of sex aneuploidies have been accepted for publication in Prenatal Diagnosis and is available online.

A large patient study published in Ophthalmology in March 2013 describes enhancements to the clinical utility of the RetnaGene AMD test by demonstrating that the test can now be used to predict progression risk to choroidal neovascularization (CNV) or late stage '"wet" AMD in patients with early stage disease.

Sequenom CMM had a strong presence during the annual clinical meeting of the American College of Medical Genetics and Genomics in March, during which NIPT was a prominent topic. Sequenom CMM hosted a dynamic symposium on NIPT attended by approximately 700 medical professionals and presented a series of posters highlighting its clinical experience with the first 60,000 MaterniT21 PLUS test samples processed.

Sequenom CMM also accessioned a record number of patient samples for cystic fibrosis testing, based on the introduction of the Heredi-T™ cystic fibrosis (CF) carrier screening test. The Heredi-T CF laboratory-developed test now analyzes 136 mutations and five variants proven to be clinically relevant in causing CF, integrating disease causing mutations selected from the Johns Hopkins CFTR2 database. The test analyzes nearly six times the number of clinically relevant mutations currently available in the most common commercial CF carrier screening test methods.

In response to the growing commercial interest and demand for its testing services, Sequenom CMM expanded its diagnostics sales force during the first quarter of 2013, bringing the total to approximately 84 diagnostic sales representatives actively selling in all 50 states. The Company continues to expand into international markets as well.

Sequenom CMM has implemented an in-house billing system, effective May 1, 2013, utilizing a leading hosted software solution. This new system is expected to enable Sequenom CMM to maximize reimbursement, improve cash flow and improve efficiencies in the billing and collections process.

Sequenom CMM has completed the build-out and validation of the additional laboratory location in North Carolina, which has recently received its CLIA registration for operation. This additional location is expected to begin commercial operations mid-year.

As a result of the Company's efforts, the U.S. patent and trademark office (PTO) declared a patent interference on May 3, 2013, between issued U.S. Patent number 8,195,415, which is asserted against the Company in litigation, and U.S. patent application number 13/070,266, which is exclusively licensed to Sequenom, Inc. On the same date, the PTO also re-declared patent interference number 105,920, between issued U.S. Patent no. 8,008,018, which is also asserted against the Company in litigation, and U.S. patent application no. 13/070,275, which is exclusively licensed to Sequenom, Inc. On May 3, 2013, the PTO also declared two additional patent interferences (nos. 105,923 and 105,924) between patent applications licensed to another party and patent applications licensed to Sequenom, Inc.

"We are encouraged by these decisions by the PTO and look forward to continued developments in this important area," said Bill Bowen, Senior Vice President and General Counsel of Sequenom, Inc.

Conference Call Information
A conference call hosted by Harry F. Hixson, Jr., Ph.D., Chairman and CEO, and other members of senior management will take place today, May 9, at 5:00 pm ET (2:00 pm PT) and will be webcast live on the Sequenom website. To access the live teleconference call, dial 800-860-2442 in the U.S. and 412-858-4600 for international callers. Please specify to the operator that you would like to join the "Sequenom First Quarter 2013 Earnings Conference Call." If you are unable to listen to the live webcast, a teleconference replay will be available until Thursday, May 16, 2013. Interested parties can access the replay by dialing 877-344-7529 or 412-317-0088 internationally and entering the conference number 10028207.

The conference call webcast is accessible through the "Investors" section of the Sequenom website at http://ir.sequenom.com. An online replay will be available following the initial broadcast until Thursday, June 20, 2013.

About Sequenom Center for Molecular Medicine
Sequenom Center for Molecular Medicine (Sequenom CMM^®) is a CAP accredited and CLIA-certified molecular diagnostics reference laboratory currently with two locations dedicated to the development and commercialization of laboratory-developed tests for prenatal and eye conditions and diseases. Utilizing innovative proprietary technologies, Sequenom CMM provides test results that can be used by health care professionals in managing patient care. Testing services are available only upon request by physicians. Sequenom CMM works closely with key opinion leaders and experts in obstetrics, retinal care and genetics. Sequenom CMM scientists use a variety of sophisticated and cutting-edge methodologies in the development and validation of tests. Sequenom CMM is changing the landscape in genetic diagnostics. Visit http://www.sequenomcmm.com for more information on laboratory testing services.

SEQUENOM^®, MaterniT21™, MaterniT21™ PLUS, RetnaGene™ and Heredi-T™ are trademarks of Sequenom, Inc. All other trademarks and service marks are the property of their respective owners.

Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the Company's progress in negotiations with payors, indications of steady growth and sustained momentum in 2013 for the Company's diagnostics business, the Company's expectations to complete the moving of its billing and collections processes in-house and its anticipation of greater control in monitoring payments from payors and improved workflows that will improve collections, maximize reimbursement and improve cash flow and efficiencies, the annualized run rate for the MaterniT21 PLUS test at the end of the first quarter and Sequenom CMM's expectation to exceed 150,000 samples accessioned for all of 2013, the Company's continuing expansion in international markets, Sequenom CMM's expectation for the North Carolina laboratory to begin commercial operations mid-year 2013, the Company's commitment to improving healthcare through revolutionary genetic analysis solutions, and Sequenom CMM's dedication to the development and commercialization of laboratory-developed tests for prenatal and eye conditions and diseases and changing the landscape in genetic diagnostics, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market demand for and acceptance and use of technology and tests such as the MaterniT21 PLUS test, reliance upon the collaborative efforts of other parties such as, without limitation, healthcare providers, international distributors and licensees, the Company or third parties obtaining or maintaining regulatory approvals that impact the Company's business, government regulation particularly with respect to diagnostic products and laboratory developed tests, publication processes, the performance of designed product enhancements, the Company's ability to develop and commercialize technologies and products, particularly new technologies such as noninvasive prenatal diagnostics, laboratory developed tests, and genetic analysis platforms, the Company's financial position, the timing and amount of reimbursement that Sequenom CMM receives from payors for its laboratory developed tests, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, litigation involving the Company, and other risks detailed from time to time in the Company's most recently filed Quarterly Report on Form 10-Q, its most recently filed reports on Form 8-K, and its most recently filed Annual Report on Form 10-K, and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

[Financial tables follow]

SEQUENOM, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
*(In thousands, except per share information)*

	Three Months Ended March 31,
	2013		2012
Revenues:
Diagnostic services	$	29,083	$	4,780
Genetic analysis product sales and services	9,415		10,140
Total revenues	38,498		14,920
Cost of revenues:
Cost of diagnostic services	21,079		6,871
Cost of genetic analysis product sales and services	3,459		3,423
Total cost of revenues	24,538		10,294
Gross margin	13,960		4,626
Operating expenses:
Selling and marketing	13,657		9,677
Research and development	13,834		11,844
General and administrative	13,483		7,350
Total operating expenses	40,974		28,871
Loss from operations	(27,014)		(24,245)
Other income (expense), net	(2,334)		(176)
Loss before income taxes	(29,348)		(24,421)
Income tax expense	(12)		(2)
Net loss	$	(29,360)	$	(24,423)
Net loss per common share, basic and diluted	$	(0.26)	$	(0.22)
Weighted average number of shares outstanding, basic and diluted	115,040		110,512

SEQUENOM, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
*(In thousands)*

	March 31, 2013		December 31, 2012

Assets
Current assets:
Cash, cash equivalents and marketable securities	$	151,075	$	175,942
Accounts receivable, net	7,127		7,887
Inventories	12,582		10,570
Other current assets and prepaid expenses	3,639		3,075
Total current assets	174,423		197,474
Property, equipment and leasehold improvements, net	35,243		33,494
Other assets	18,325		17,987
Total assets	$	227,991	$	248,955
Liabilities and stockholders' equity
Current liabilities:
Accounts payable	$	20,479	$	16,469
Accrued expenses	27,316		24,507
Long-term debt and obligations, current portion	7,607		7,601
Other current liabilities	2,878		2,713
Total current liabilities	58,280		51,290
Long-term liabilities	147,300		149,658
Total stockholders' equity	22,411		48,007
Total liabilities and stockholders' equity	$	227,991	$	248,955

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

SOURCE Sequenom, Inc.

Sequenom Announces Participation At The Bank Of America Merrill Lynch Health Care Conference

Wed, 08 May 2013 07:00:00 -0400

May 8, 2013

SAN DIEGO, May 8, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced the Company's participation at the Bank of America Merrill Lynch Health Care Conference at the Encore at the Wynn Hotel in Las Vegas, NV on May 14-16, 2013.

Paul V. Maier, Chief Financial Officer, will present on Thursday, May 16, 2013 beginning at 12:00 p.m. PDT, to provide an overview of and update on the Company. The presentation is expected to last approximately 30 minutes and will be web cast live through the "Investors" section of the Sequenom website at www.sequenom.com. An audio replay will be available for 30 days following the initial presentation web cast.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

SOURCE Sequenom, Inc.

Sequenom, Inc. Announces Date of First Quarter 2013 Financial Results and Conference Call

Thu, 25 Apr 2013 07:00:00 -0400

Apr 25, 2013

SAN DIEGO, April 25, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced it will report financial results for the first quarter of 2013 after closing of the NASDAQ Global Market on Thursday, May 9, 2013.

A conference call hosted by Harry F. Hixson, Jr., Ph.D., Chairman and CEO, and other members of senior management will take place on the same day at 5:00 pm ET (2:00 pm PT) and will be webcast live on the Sequenom website.

To access the live teleconference call, dial 800-860-2442 in the U.S. and 412-858-4600 for international callers. Please specify to the operator that you would like to join the "Sequenom First Quarter 2013 Earnings Conference Call." If you are unable to listen to the live webcast, a teleconference replay will be available until Friday, May 17, 2013. Interested parties can access the replay by dialing 877-344-7529 or 412-317-0088 internationally and entering the conference number 10028207.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

SOURCE Sequenom, Inc.

Sequenom CMM Achieves Milestone Of 100,000 MaterniT21™ Plus Tests Processed

Tue, 16 Apr 2013 07:00:00 -0400

Apr 16, 2013

SAN DIEGO, April 16, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that earlier this month, its wholly owned subsidiary, the Sequenom Center for Molecular Medicine (Sequenom CMM), surpassed 100,000 MaterniT21™ PLUS test samples processed since the launch of its laboratory developed test (LDT) in October of 2011. The MaterniT21 PLUS test was the first commercial non-invasive prenatal test (NIPT) of its kind for the detection of a genetic chromosomal anomaly known as Trisomy 21, the most common cause of Down syndrome.

"There has been a significant clinical benefit of incorporating NIPT technology, such as the MaterniT21 PLUS test, into my practice, and I expect to see this technology utilized as a best practice tool among women at high risk of fetal aneuploidy," said Arnold Cohen, MD, Chairman, Department of Obstetrics and Gynecology, Albert Einstein Medical Center in Philadelphia. "The MaterniT21 PLUS test has enabled me to provide more accurate prenatal test results in a timely manner. It's reliability and ease of use is of great value to my patients and their families."

The MaterniT21 PLUS test has shown high accuracy, precision and sensitivity, and it is offered by Sequenom CMM as outlined by The American College of Obstetricians and Gynecologists Committee on Genetics and the Society for Maternal-Fetal Medicine Publications Committee joint recommendation supporting NIPT in pregnant women at high risk of carrying a fetus with fetal aneuploidy.

"This milestone represents the overwhelmingly positive response we have received from the obstetrics community to the MaterniT21 PLUS test, and we believe the physician loyalty and interest in our offerings validate the superior attributes of our testing services and support," said William Welch, President and COO, Sequenom, Inc. "With the expansion of our testing capacity and continued investment in our team dedicated solely to providing physicians with education and support for the MaterniT21 PLUS test, we expect that Sequenom CMM will surpass the next milestone of accessioning 150,000 test samples in 2013."

In response to the rapid volume growth and medical community adoption of the MaterniT21 PLUS test, Sequenom CMM is in the process of increasing its testing capacity by completing the validation and licensure of an additional location in North Carolina. This additional location is expected to be operational in the second half of 2013 and will increase the total NIPT capacity from the current 200,000 test samples per year to a minimum of 300,000 test samples per year. At the close of December 2012, the annualized run rate for the MaterniT21 PLUS test was more than 120,000 test samples, an average of more than 2,300 samples weekly.

SEQUENOM^®, MaterniT21™ and MaterniT21™ PLUS are trademarks of Sequenom, Inc. All other trademarks and service marks are the property of their respective owners.

About Sequenom Center for Molecular Medicine
Sequenom Center for Molecular Medicine (Sequenom CMM^®) is a CAP accredited and CLIA-certified molecular diagnostics reference laboratory currently with two locations dedicated to the development and commercialization of laboratory developed tests for prenatal and eye conditions and diseases. Utilizing innovative proprietary technologies, Sequenom CMM provides test results that can be used by health care professionals in managing patient care. Testing services are available only upon request by physicians. Sequenom CMM works closely with key opinion leaders and experts in obstetrics, retinal care and genetics. Sequenom CMM scientists use a variety of sophisticated and cutting-edge methodologies in the development and validation of tests. Sequenom CMM is changing the landscape in genetic diagnostics. Visit http://www.sequenomcmm.com for more information on laboratory testing services.

Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding increasing demand from for Sequenom CMM's prenatal tests, growing Sequenom CMM's market presence, sales expansion and establishing its leadership position, the Company's 2013 expectations regarding test volumes, capacity expansion including the opening, build-out, and licensure of a third laboratory location in North Carolina for Sequenom CMM, the Company's commitment to improving healthcare through revolutionary genetic analysis solutions, and Sequenom CMM's dedication to the development and commercialization of laboratory developed tests for prenatal and eye conditions and diseases, and changing the landscape in genetic diagnostics, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market demand for and acceptance and use of technology and tests such as the MaterniT21 PLUS test, reliance upon the collaborative efforts of other parties such as, without limitation, healthcare providers, international distributors and licensees, the Company or third parties obtaining or maintaining regulatory approvals that impact the Company's business, government regulation particularly with respect to diagnostic products and laboratory developed tests, publication processes, the performance of designed product enhancements, the Company's ability to develop and commercialize technologies and products, particularly new technologies such as noninvasive prenatal diagnostics, laboratory developed tests, and genetic analysis platforms, the Company's financial position, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, litigation involving the Company, and other risks detailed from time to time in the Company's most recently filed Quarterly Report on Form 10-Q for the quarter ended September 30, 2012, its most recently filed reports on Form 8-K, and its most recently filed Annual Report on Form 10-K, and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

SOURCE Sequenom, Inc.

Sequenom, Inc. Announces The Availability Of Heredi-T™ Cystic Fibrosis Carrier Screening LDT Through Sequenom CMM

Thu, 21 Mar 2013 07:00:00 -0400

Mar 21, 2013

SAN DIEGO, March 21, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that Sequenom Center for Molecular Medicine (SCMM) has launched an advanced new cystic fibrosis carrier screen test branded under the name Heredi-T™. The laboratory-developed test (LDT) is now available as a testing service to ordering physicians.

The Heredi-T Cystic Fibrosis (CF) test analyzes 136 mutations and five variants proven to be clinically relevant in causing CF, integrating disease causing mutations selected from the Johns Hopkins CFTR2 database (http://www.cftr2.org). The LDT analyzes nearly six times the number of mutations currently available in other screening methods and can be performed preconception or at any time during pregnancy with a DNA sample obtained from a buccal swab.

"The Heredi-T test provides significant new clinical value, offering highly reliable information about a patient's risk of being a cystic fibrosis carrier," said Bill Welch, President and COO of Sequenom. "This introduction adds to Sequenom CMM's leadership in prenatal testing and supports our mission to help health care providers and their patients make more informed clinical decisions through the use of advanced genetics."

The American College of Obstetricians and Gynecologists (ACOG) recommends cystic fibrosis carrier screening for all patients. According to ACOG, additional screening consideration should be given to patients with the following, as these clinical indicators increase the risk of CF:

Family history of CF in the patient or partner's family
Ultrasound findings that indicate an increased risk for CF
Bowel or dilated loops of bowel
History of male infertility

Results of the Heredi-T CF test are delivered to the physician on average within seven business days. A positive Heredi-T CF test result indicates that the patient has one copy of a genetic mutation that is known to cause CF, and they should be advised to consider genetic counseling or further testing. A negative Heredi-T CF test result indicates a low risk for CF, but does not completely eliminate the risk because the test does not screen for all possible CF mutations.

About Cystic Fibrosis
Cystic fibrosis (CF) is one of the most common genetic diseases in the United States. It is caused by changes in the CFTR gene. Changes in this gene cause the body to produce thick sticky mucus in the lungs, pancreas and other organs that can affect breathing and digestion. Symptoms can range from moderate to severe and can even impact fertility. It is estimated that more than 10 million Americans are carriers of CF. While the risk of being a CF carrier is dependent upon one's ethnicity and family history, individuals of all racial and ethnic groups may be carriers of CF.

About Sequenom Center for Molecular Medicine
Sequenom Center for Molecular Medicine® (Sequenom CMM), a CAP accredited and CLIA-certified molecular diagnostics laboratory, has developed a broad range of laboratory tests with a focus on prenatal and ophthalmological diseases and conditions. Branded under the names MaterniT21™ PLUS, Heredi-T™, SensiGene® and RetnaGene™, these molecular genetic laboratory tests provide early patient management information for obstetricians, geneticists, maternal fetal medicine specialists, retina specialists and ophthalmologists. Sequenom CMM is changing the landscape in genetic disorder diagnostics using proprietary cutting edge technologies. Visit http://www.sequenomcmm.com for more information on laboratory testing services.

SEQUENOM^®, SEQUENOM^®CMM^®, MaterniT21™ PLUS, Heredi-T™, SensiGene^® and RetnaGene™ are trademarks of Sequenom, Inc. All other trademarks and service marks are the property of their respective owners.

Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the expected benefits, impact, and value of the Heredi-T™ CF test to healthcare providers and their patients, the Company's commitment to improving healthcare through revolutionary genetic analysis solutions, and Sequenom CMM's impact on the landscape in genetic diagnostics, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market demand for and acceptance and use of technology and tests such as the Heredi-T™ CF test, reliance upon the collaborative efforts of other parties such as, without limitation, healthcare providers, international distributors and licensees, the Company or third parties obtaining or maintaining regulatory approvals that impact the Company's business, government regulation particularly with respect to diagnostic products and laboratory developed tests, publication processes, the performance of designed product enhancements, the Company's ability to develop and commercialize technologies and products, particularly new technologies such as noninvasive prenatal diagnostics, laboratory developed tests, and genetic analysis platforms, the Company's financial position, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, litigation involving the Company, and other risks detailed from time to time in the Company's most recently filed Quarterly Report on Form 10-Q for the quarter ended September 30, 2012, its most recently filed reports on Form 8-K, and its most recently filed Annual Report on Form 10-K, and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

SOURCE Sequenom, Inc.

Sequenom Announces Participation At The 25th Annual Roth Conference

Fri, 15 Mar 2013 14:46:00 -0400

Mar 15, 2013

SAN DIEGO, March 15, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced the Company's participation at the 25^th Annual Roth Conference at the Ritz-Carlton Hotel in Laguna Niguel, CA on March 17-20, 2013.

William Welch, M.B.A, President and Chief Operating Officer, will present on Monday, March 18, 2013, beginning at 12:30 p.m. PT, to provide an overview of and update on the Company. The presentation is expected to last approximately 25 minutes and will be web cast live through the "Investors" section of the Sequenom website at www.sequenom.com. An audio replay will be available for 30 days following the initial presentation web cast.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

SOURCE Sequenom, Inc.

Sequenom, Inc. Reports Financial Results For The Fourth Quarter And Full Year Of 2012

Thu, 07 Mar 2013 16:10:00 -0500

Diagnostic Services Now Largest Contributor to Total Revenues

Mar 7, 2013

SAN DIEGO, March 7, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today reported total revenues of $33.7 million and $89.7 million for the fourth quarter and full year of 2012, respectively. Net loss was $32.8 million, or $0.29 per share, and $117.1 million, or $1.03 per share, for the fourth quarter and full year, respectively.

"It has been a little more than one year since the Sequenom Center for Molecular Medicine (SCMM) launched MaterniT21 PLUS™, the first non-invasive prenatal test (NIPT) in the United States that measures circulating cell-free nucleic acids in maternal blood for the detection of fetal aneuploidies. During 2012, SCMM established itself as the leader in the NIPT field with the good acceptance of MaterniT21 PLUS by the medical community," said Harry Hixson, Jr., Ph.D., Chairman and CEO of Sequenom. "SCMM and its licensees have also seen rapid acceptance of non-invasive prenatal testing in countries outside the United States."

Fourth Quarter 2012 Performance
Total revenues for the fourth quarter of 2012 increased to $33.7 million, 117% over revenues of $15.5 million for the comparable period in 2011. Fourth quarter 2012 revenues from the genetic analysis operating segment were essentially flat year-over-year, while revenues from the SCMM diagnostics services operating segment grew to $21.1 million in the fourth quarter of 2012 up from $2.8 million in the prior year period. Revenues from the SCMM diagnostics segment are recorded primarily on the cash basis.

Total cost of revenues increased to $21.4 million for the fourth quarter of 2012, compared to $9.3 million for the prior year period. Cost of revenues increased due to the significant increase in the number of diagnostic tests performed, with accessions of 33,000 samples during the fourth quarter of 2012 compared to 8,000 samples accessioned during the prior year period.

Today we filed a Form 8-K which describes that management identified an accounting error in our previously issued consolidated financial statements. The resulting change in classification increased cost of revenues and decreased selling and marketing expense by the same amount and thus had no effect on revenues or net loss for this, or any period. This accounting error related to the classification of costs related to field service personnel for our genetic analysis business as selling and marketing expenses rather than as cost of revenues in prior periods. The cost of genetic analysis product sales and services for the fourth quarter of 2011 now includes an additional $0.8 million in maintenance labor services. These costs were previously classified as selling and marketing expenses.

Overall gross margin for the fourth quarter of 2012 was 37% as compared to gross margin of 40% for the fourth quarter of 2011. Fourth quarter gross margin for our diagnostics services business was positive for the first time since the launch of SCMM's MaterniT21 PLUS test, even with revenues being recorded on the cash basis. Gross margin for our genetic analysis business for the fourth quarter of 2012 was 67% compared to 70% for the prior year period.

Total operating expenses for the fourth quarter of 2012 were $41.8 million, as compared to total operating expenses of $28.2 million for the fourth quarter of 2011. Selling and marketing expenses increased to $13.8 million for the fourth quarter of 2012 from $8.2 million for the fourth quarter of 2011, resulting primarily from higher labor costs associated with the expansion of the SCMM sales force and marketing efforts. Research and development expenses increased to $14.3 million for the fourth quarter of 2012, as compared to $13.1 million in the fourth quarter of 2011, resulting primarily from the expansion of capacity and the progress toward validation of the MaterniT21 PLUS test at the North Carolina facility.

General and administrative expenses for the fourth quarter of 2012 were $13.7 million, as compared to $6.8 million for the fourth quarter of 2011, due to increased litigation expenses and increased infrastructure to support the Company's operations. Total stock-based compensation expense was $4.1 million for the fourth quarter of 2012; an increase from $2.8 million in stock-based compensation recorded for the fourth quarter of 2011 as a result of a change in estimate for performance based stock awards.

Net loss for the fourth quarter 2012 was $32.8 million or $0.29 per share, as compared to net loss of $22.2 million, or $0.22 per share for the same period in 2011. Net cash used in operating activities was $14.5 million for the fourth quarter 2012, lower than the previous quarters in 2012.

"We made significant progress in our performance during 2012, with strong revenue growth during the fourth quarter as our diagnostic services revenues increased and our overall cash burn declined," said Paul V. Maier, Sequenom's CFO. "We look forward to continued growth in 2013 through greater testing volumes and revenues, as well as test capacity expansion. To meet the growing demand for its testing services, we expect Sequenom CMM's third laboratory location in North Carolina will become operational later this year."

Full year 2012 Performance
The Company reported revenues of $89.7 million for 2012, an increase of 60% compared to revenues of $55.9 million for 2011. Diagnostic services revenues were 52% of total revenues for 2012, surpassing revenues from the genetic analysis operating segment for the first time in the Company's history. The Company will continue to account for revenues from its diagnostic testing services on a cash basis until further experience and third party contracts are gained and additional internal controls are established that will allow a reasonable estimate of collectable amounts to be made before moving to the accrual method of accounting.

Cost of revenues increased to $62.3 million for 2012, compared to $26.4 million for 2011, due to the greatly increased number of diagnostic tests performed. SCMM accessioned 92,000 samples during 2012 as compared to 23,300 samples accessioned during the prior year. The cost of revenues for 2011 reflects the restatement for the change in classification of the cost of maintenance services for the genetic analysis business in the amount of $3.1 million as described above.

Overall gross margin for 2012 was 31% of revenues, decreasing from 53% of revenues for the full year 2011, primarily as a result of the additional costs of diagnostic services which are expensed when incurred, whereas diagnostic services revenues are primarily recorded on a cash basis.

Total operating expenses for 2012 were $140.1 million, as compared to total expenses of $103.8 million for 2011. This increase was primarily the result of higher selling and marketing expenses to penetrate the market for noninvasive prenatal testing, in particular, and higher legal costs associated with patent litigation.

Selling and marketing expenses increased to $44.9 million for 2012 from $28.0 million for 2011, due primarily to higher labor costs associated with the expansion of SCMM's prenatal and ophthalmology specialty sales forces. Research and development expenses increased to $54.1 million for 2012 from $53.6 million in 2011. The incremental expense is related primarily to higher labor costs to support research and development activities offset by lower intellectual property licensing and collaboration costs compared to 2011. General and administrative expenses for 2012 were $41.1 million, as compared to $22.2 million for 2011, due to increased patent litigation expenses and increased infrastructure to support the Company's operations. Total stock-based compensation expense was $13.3 million for 2012, an increase from the $12.1 million recorded during the full year 2011.

Net loss for 2012 was $117.1 million or $1.03 per share, as compared to net loss of $74.2 million, or $0.75 per share for 2011.

As of December 31, 2012, the Company's total cash, cash equivalents and marketable securities were $175.9 million. Net cash used in operating activities was $78.1 million for 2012, while purchases of capital equipment for the same period totaled $15.2 million, funded partially through utilization of the Company's credit facility.

This press release contains certain unaudited financial results for the Company's fiscal year and fourth quarter ended December 31, 2012. These unaudited results may change as a result of further review by the Company's management and its independent auditors. The completion of the audit of our financial results for 2012 could result in changes to the unaudited financial results presented in this press release and may identify issues related to the effectiveness of the Company's internal controls over financial reporting. Final fourth quarter and annual results will be provided in the company's annual report to the SEC on Form 10-K.

Operational Update
SCMM accessioned approximately 92,000 total test samples in 2012, including more than 61,000 MaterniT21 PLUS test samples. At the close of December 2012, the annualized run rate for the MaterniT21 PLUS test was more than 120,000 test samples accessioned, an average of more than 2,300 samples weekly.

During the fourth quarter, Sequenom recorded significant increases in revenues, in the amount of $18.2 million, based on cash collections for samples accessioned in prior periods and the increase in total volumes of samples processed by SCMM. Positive decisions supporting the use of noninvasive prenatal testing in high-risk pregnant women were granted jointly from the American College of Obstetricians and Gynecologists Committee on Genetics and the Society for Maternal-Fetal Medicine Publications Committee, as well as The California Technology Assessment Forum. Recent positive coverage decisions have been issued by national and regional payors for high-risk pregnancies, and are expected to contribute to stronger revenues over time.

Most recently, SCMM announced that the MaterniT21 PLUS test now reports on the presence of fetal sex chromosomal aneuploidies, in addition to its identification of aneuploidies for chromosomes 21, 18 and 13.

In response to sustained growth in sample volume, SCMM is in the process of increasing its MaterniT21 PLUS test capacity by completing the build out and initiating the validation of an additional location in North Carolina. This new location is expected to be operational in the second half of 2013 and will increase the total non-invasive prenatal testing capacity to a minimum of 300,000 tests per year.

SCMM also continues to expand access to its testing services for physicians and their patients by hiring additional field sales representatives. The sales force is expected to grow to more than 85 representatives across the U.S. by the end of the first quarter 2013.

Conference Call Information
A conference call hosted by Harry F. Hixson, Jr., Ph.D., Chairman and CEO, and other members of senior management will take place today at 5:00 pm ET (2:00 pm PT) and will be webcast live on the Sequenom website.

To access the live teleconference call, dial 800-860-2442 in the U.S., 866-605-3852 in Canada (both are toll free), and 412-858-4600 for other international callers. Please specify to the operator that you would like to join the "Sequenom Fourth Quarter 2012 Earnings Conference Call." If you are unable to listen to the live webcast, a teleconference replay will be available through Friday, March 15, 2013. Interested parties can access the replay by dialing 877-344-7529 or 412-317-0088 internationally and entering the conference number 10025204.

SEQUENOM^®, MaterniT21™ and MaterniT21™ PLUS are trademarks of Sequenom, Inc. All other trademarks and service marks are the property of their respective owners.

About Sequenom Center for Molecular Medicine
Sequenom Center for Molecular Medicine (Sequenom CMM^®) is a CAP accredited and CLIA-certified molecular diagnostics reference laboratory currently with two locations dedicated to the development and commercialization of laboratory developed tests for prenatal and eye conditions and diseases. Utilizing innovative proprietary technologies, Sequenom CMM provides test results that can be used by health care professionals in managing patient care. Testing services are available only upon request by physicians. Sequenom CMM works closely with key opinion leaders and experts in obstetrics, retinal care and genetics. Sequenom CMM scientists use a variety of sophisticated and cutting-edge methodologies in the development and validation of tests. Sequenom CMM is changing the landscape in genetic diagnostics. Visit http://www.sequenomcmm.com for more information on laboratory testing services.

Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding continually increasing demand from providers around the world for Sequenom CMM's prenatal tests, growing Sequenom CMM's market presence, sales expansion and establishing its leadership position, the Company's 2013 expectations regarding greater test volumes, revenues, capacity expansion including the opening, build-out, and licensure of a third laboratory location in North Carolina for Sequenom CMM, the Company's expectations and timing regarding a move from a cash basis to an accrual method of accounting for diagnostic testing services, expectations regarding the impact of positive payor coverage decisions on future revenues and developing relationships with payors, the Company's commitment to improving healthcare through revolutionary genetic analysis solutions, and Sequenom CMM's dedication to the development and commercialization of laboratory developed tests for prenatal and eye conditions and diseases, and changing the landscape in genetic diagnostics, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market demand for and acceptance and use of technology and tests such as the MaterniT21 PLUS test, reliance upon the collaborative efforts of other parties such as, without limitation, healthcare providers, international distributors and licensees, the Company or third parties obtaining or maintaining regulatory approvals that impact the Company's business, government regulation particularly with respect to diagnostic products and laboratory developed tests, publication processes, the performance of designed product enhancements, the Company's ability to develop and commercialize technologies and products, particularly new technologies such as noninvasive prenatal diagnostics, laboratory developed tests, and genetic analysis platforms, the Company's financial position, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, litigation involving the Company, and other risks detailed from time to time in the Company's most recently filed Quarterly Report on Form 10-Q for the quarter ended September 30, 2012, its most recently filed reports on Form 8-K, and its most recently filed Annual Report on Form 10-K, and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

[Financial tables follow]

SEQUENOM, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS *(unaudited)* *(in thousands, except per share data)*


	Three months ended		For the years ended
	December 31,		December 31,
	2012	2011	2012	2011
		As Restated		As Restated
Revenues:
Diagnostic services	$ 21,066	$ 2,833	$ 46,457	$ 8,319
Genetic analysis product sales and services	12,606	12,651	43,240	47,588
Total revenues	33,672	15,484	89,697	55,907

Costs and expenses:
Cost of diagnostics services	17,169	5,409	47,283	10,031
Cost of genetic analysis product sales and services	4,193	3,845	15,025	16,360
Total cost of revenues	21,362	9,254	62,308	26,391
Gross margin	12,310	6,230	27,389	29,516

Selling and marketing	13,772	8,236	44,939	28,010
Research and development	14,339	13,074	54,115	53,585
General and administrative	13,665	6,848	41,090	22,185
Total operating expenses	41,776	28,158	140,144	103,780
Loss from operations	(29,466)	(21,928)	(112,755)	(74,264)

Other (loss) income, net	(3,610)	(206)	(4,580)	202
Loss before income taxes	(33,076)	(22,134)	(117,335)	(74,062)
Income tax benefit (expense)	311	(42)	269	(95)
Net loss	$ (32,765)	$ (22,176)	$ (117,066)	$ (74,157)

Net loss per share, basic and diluted	$ (0.29)	$ (0.22)	$ (1.03)	$ (0.75)

Weighted average shares outstanding, basic and diluted	114,786	99,325	113,646	99,143

SEQUENOM, INC. CONDENSED CONSOLIDATED BALANCE SHEETS *(unaudited)* *(in thousands)*


	December 31,	December 31,
	2012	2011
		As Restated
Assets:
Cash, cash equivalents, marketable securities	$ 175,942	$ 84,216
Accounts receivable, net	7,887	6,972
Inventories	10,570	8,729
Prepaid expenses and other assets	3,075	3,533
Total current assets	197,474	103,450

Property, equipment and leasehold improvements, net	33,158	23,902
Other assets	17,987	12,468
Total assets	$ 248,619	$ 139,820

Liabilities and Stockholders' Equity:
Accounts payable	$ 16,133	$ 8,435
Accrued expenses	24,481	15,975
Long-term debt and obligations, current portion	7,625	2,147
Other current liabilities	2,713	2,924
Total current liabilities	50,952	29,481

Long-term liabilities	149,720	19,183
Stockholders' equity	47,947	91,156
Total liabilities and stockholders' equity	$ 248,619	$ 139,820

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

SOURCE Sequenom, Inc.

Sequenom Announces Participation At The Barclays Global Healthcare Conference

Tue, 05 Mar 2013 07:00:00 -0500

Mar 5, 2013

SAN DIEGO, March 5, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced the Company's participation at the Barclays Global Healthcare Conference at the Loews Miami Hotel in Miami, FL on March 12-14, 2013.

Ronald M. Lindsay, Ph.D., Director and EVP of Strategic Planning, will present on Wednesday, March 13, 2013, beginning at 4:45 p.m. ET, to provide an overview of and update on the Company. The presentation is expected to last approximately 25 minutes and will be web cast live through the "Investors" section of the Sequenom website at www.sequenom.com. An audio replay will be available for 30 days following the initial presentation web cast.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

SOURCE Sequenom, Inc.

Sequenom, Inc. Announces Date Of Fourth Quarter And Full Year 2012 Financial Results And Conference Call

Wed, 20 Feb 2013 07:00:00 -0500

Feb 20, 2013

SAN DIEGO, Feb. 20, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced it will report financial results for the fourth quarter and full year of 2012 after closing of the NASDAQ Global Market on Thursday, March 7, 2013.

About Sequenom

About Sequenom Center for Molecular Medicine

Sequenom Center for Molecular Medicine (Sequenom CMM^®) is a CAP accredited and CLIA-certified molecular diagnostics laboratory with two locations dedicated to the development and commercialization of laboratory developed tests for prenatal and eye conditions and diseases. Utilizing innovative proprietary technologies, Sequenom CMM provides test results that can be used as tools by clinicians in managing patient care. Testing services are available only upon request to physicians. Sequenom CMM works closely with key opinion leaders and experts in obstetrics, retinal care and genetics. Sequenom CMM scientists use a variety of sophisticated and cutting-edge methodologies in the development and validation of tests. Sequenom CMM is changing the landscape in genetic diagnostics. Visit http://www.scmmlab.com for more information on laboratory testing services.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

SOURCE Sequenom, Inc.

Sequenom CMM's MaterniT21 PLUS LDT Now Reporting On Gender-Specific Chromosomal Abnormalities

Mon, 04 Feb 2013 07:00:00 -0500

Feb 4, 2013

SAN DIEGO, Feb. 4, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, announced today that the MaterniT21™ PLUS laboratory-developed test (LDT) available exclusively through Sequenom Center for Molecular Medicine (Sequenom CMM) will now report as additional findings the presence of certain fetal sex chromosomal aneuploidies, in addition to its identification of autosomal aneuploidies for chromosome 21 (associated with Down syndrome), chromosome 18 (associated with Edwards syndrome), and chromosome 13 (associated with Patau syndrome). Reporting of these sex aneuploidies will begin for samples received as of Monday, February 4, 2013.

The test will report on the presence of four rare aneuploidies involving an abnormal number of X or Y chromosomes, including female syndromes 45,X (Turner Syndrome) and 47,XXX (Triple X Syndrome), and male syndromes 47,XXY (Klinefelter Syndrome) and 47,XYY. Results of the blinded clinical validation study set have been submitted for publication in a peer-reviewed journal.

"Sex chromosome abnormalities may be recognized at birth, as part of the spectrum of less severe chromosome abnormalities. They can also be found in adults, many being incidentally discovered in the course of evaluating patients for infertility or endocrine problems. Identifying these conditions through the MaterniT21 PLUS test will allow the health care provider and patient to discuss the medical issues associated with these conditions as well as to develop both short- and long-term care plans," said Allan Bombard, MD, Sequenom's Chief Medical Officer.

The MaterniT21 PLUS test analyzes the relative amount of 21, 18, 13, as well as X and Y chromosomal material in cell-free DNA. The test is intended for use in pregnant women at increased risk for fetal aneuploidy and can be used as early as 10 weeks' gestation. Estimates suggest there are about 750,000 pregnancies at high risk for fetal aneuploidy each year in the United States. The MaterniT21 PLUS test is available exclusively through the Sequenom Center for Molecular Medicine (Sequenom CMM) as a testing service provided to physicians. To learn more about the test, please visit www.Sequenomcmm.com.

About Sequenom

About Sequenom CMM

Sequenom Center for Molecular Medicine® (Sequenom CMM), a CAP accredited and CLIA-certified molecular diagnostics laboratory, has developed a broad range of laboratory tests with a focus on prenatal and ophthalmological diseases and conditions. Branded under the name SensiGene™, MaterniT21™ PLUS, and RetnaGene™, these molecular genetic laboratory tests provide early patient management information for obstetricians, geneticists and maternal fetal medicine specialists. Sequenom CMM is changing the landscape in genetic disorder diagnostics using proprietary cutting edge technologies.

Forward-Looking Statement

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the expected publication and timing thereof of the validation data for the fetal sex chromosomal aneuploidies, the expected date of February 4, 2013 for reporting fetal sex chromosomal aneuploidies, the impact, benefits, and effect of identifying fetal sex chromosomal aneuploidies on patient care and planning, the Company's commitment to improving healthcare through revolutionary genetic analysis solutions, and Sequenom CMM changing the landscape in genetic disorder diagnostics, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market demand for and acceptance and use of technology and tests such as the MaterniT21 PLUS test, reliance upon the collaborative efforts of other parties such as, without limitation, healthcare providers, international distributors and licensees, the Company or third parties obtaining or maintaining regulatory approvals that impact the Company's business, government regulation particularly with respect to diagnostic products and laboratory developed tests, publication processes, the performance of designed product enhancements, the Company's ability to develop and commercialize technologies and products, particularly new technologies such as noninvasive prenatal diagnostics, laboratory developed tests, and genetic analysis platforms, the Company's financial position, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, litigation involving the Company, and other risks detailed from time to time in the Company's most recently filed Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 and its Annual Report on Form 10-K for the year ended December 31, 2011, and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

SOURCE Sequenom, Inc.

Sequenom Announces Preliminary 2012 Operational Highlights

Sun, 06 Jan 2013 23:00:00 -0500

Jan 6, 2013

SAN DIEGO, Jan. 6, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced preliminary highlights of the Company's 2012 performance and accomplishments.

Initial 2012 Performance Results (unaudited)

Total revenue of approximately $89 million, growth of approximately 59 percent year-over-year for 2012
Diagnostic services revenues of approximately $46 million, compared to $8.3 million in 2011. Diagnostic services revenues continue to be recorded primarily as cash is received
Sales in the Genetic Analysis business of approximately $43 million
More than 92,000 total prenatal and retinal diagnostic tests accessioned during the year
Strong increases in the adoption rate and sales of Sequenom Center for Molecular Medicine's (Sequenom CMM) MaterniT21 PLUS lab-developed test (LDT):
- More than 60,000 MaterniT21 PLUS tests accessioned in 2012
- An annualized run rate of more than 120,000 MaterniT21 PLUS tests accessioned at the end of 2012
- Approximately 56 million lives under coverage with growing number of payor contracts
- Continued reimbursement as an out-of-network laboratory from large commercial payors
Total cash, cash equivalents, and marketable securities as of December 31, 2012 were approximately $176 million
Cash burn of approximately $17 million for the fourth quarter of 2012

"2012 was a year of remarkable progress for Sequenom. The rapid adoption of the Sequenom CMM's MaterniT21 PLUS by the OB/GYN physician community far exceeded the Company's internal goal and the estimates of industry analysts. The joint recommendation by the American College of Obstetricians and Gynecologists (ACOG) and the Society of Maternal and Fetal Medicine (SMFM) for the use of noninvasive prenatal tests (NIPT) such as the MaterniT21 PLUS in high risk pregnancies provided an additional validation for this technology. The company also exceeded the majority of its other goals as it established Sequenom CMM as a leader in the prenatal testing market," said Harry F. Hixson, Jr, Ph.D., Chairman and CEO of Sequenom. "We look forward to the continued growth of the MaterniT21 PLUS LDT in 2013 and the corresponding increase in test capacity. We plan to work with national and regional payors to establish additional contracts facilitating the availability of the MaterniT21 PLUS LDT to high-risk pregnant women throughout the United States."

On Wednesday, January 9th, Chairman and CEO Harry F. Hixson, Jr., Ph.D, and Ronald M. Lindsay, Ph.D., Director and EVP of Strategic Planning, will present at the JP Morgan 31^st Annual Healthcare Conference in San Francisco, CA, starting at 11:30 am PT (2:30 pm ET) to provide an overview of and update on the Company.

The presentation is expected to last approximately 30 minutes and will be webcast live through the "Investors" section of the Sequenom website at www.sequenom.com. An audio replay will be available for 30 days following the initial presentation webcast. The presentation is currently posted on the Company's website.

About Sequenom

About Sequenom CMM

Sequenom Center for Molecular Medicine® (Sequenom CMM), a CAP accredited and CLIA-certified molecular diagnostics laboratory, is developing a broad range of diagnostics with a focus on prenatal and ophthalmological diseases and conditions. Branded under the name SensiGene™, RetnaGene™, MaterniT21 PLUS™ these genetic tests provide better patient management alternatives for obstetricians, geneticists and maternal fetal medicine specialists. Sequenom CMM is changing the landscape in genetic disorder diagnostics using proprietary cutting edge technologies.

Forward-Looking Statement

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding an annualized run rate for MaterniT21 PLUS tests accessioned, expectations of continued reimbursement from large commercial payors, expectations of continued growth of the MaterniT21 PLUS test in 2013 and corresponding increase in test capacity, the Company's plans to work with national and regional payors to establish additional contracts for test availability for pregnant women throughout the United States, further review of financial results for the fiscal year and quarter ended December 31, 2012 to be conducted by the Company's management and its independent auditors, the completion of the audit of the Company's financial results for 2012 and its potential change or impact on the unaudited financial results presented herein and/or identification of issues related to the effectiveness of the Company's internal controls over financial reporting, and the Company's commitment to improving healthcare through revolutionary genetic analysis solutions are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market demand for and acceptance and use of technology and tests such as the MaterniT21 PLUS test, reliance upon the collaborative efforts of other parties such as, without limitation, healthcare providers, international distributors and licensees, the Company or third parties obtaining or maintaining regulatory approvals that impact the Company's business, government regulation particularly with respect to diagnostic products and laboratory developed tests, publication processes, the performance of designed product enhancements, the Company's ability to develop and commercialize technologies and products, particularly new technologies such as noninvasive prenatal diagnostics, laboratory developed tests, and genetic analysis platforms, the Company's financial position, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, litigation involving the Company, and other risks detailed from time to time in the Company's most recently filed Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 and its Annual Report on Form 10-K for the year ended December 31, 2011, and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

SOURCE Sequenom, Inc.

Sequenom Announces Participation At 31st Annual JP Morgan Healthcare Conference

Wed, 02 Jan 2013 07:00:00 -0500

Jan 2, 2013

SAN DIEGO, Jan. 2, 2013 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced the Company's participation at the upcoming 31^st Annual JP Morgan Healthcare Conference, to be hosted at the Westin St. Francis Hotel in San Francisco, CA.

On Wednesday, January 9th, Chairman and CEO Harry F. Hixson, Jr., Ph.D, and Ronald M. Lindsay, Ph.D., Director and EVP of Strategic Planning, will present starting at 11:30 am PT (2:30 pm ET) to provide an overview of and update on the Company.

About Sequenom

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO )

SOURCE Sequenom, Inc.

Sequenom Provides Update On Status Of Patent For Methods Of Detecting Fetal Aneuploidy

Fri, 14 Dec 2012 20:00:00 -0500

Dec 14, 2012

SAN DIEGO, Dec. 14, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that the U.S. Patent and Trademark Office has withdrawn the issuance of U.S. Patent No. 8,340,916. Sequenom has been informed by the Patent and Trademark Office that issuance was withdrawn in connection with an anticipated patent interference proceeding between parties with pending patent applications or issued patents directed to similar subject matter.

Sequenom had previously been notified that the patent would issue on December 25, 2012, with claims to novel methods for detecting fetal aneuploidy using massively parallel sequencing. The patent is entitled Diagnosing Fetal Chromosomal Aneuploidy Using Massively Parallel Genomic Sequencing and was invented by Drs. Dennis Lo, Rossa Chiu and Alan Chan of the Chinese University of Hong Kong. Sequenom has exclusive rights to this patent.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding an anticipated patent interference proceeding and the Company's commitment to improving healthcare through revolutionary genetic analysis solutions, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market demand for and acceptance and use by customers of its products, reliance upon the collaborative efforts of other parties, the Company's financial position, its ability to position itself for product launches and growth and develop and commercialize new technologies and products, particularly newer technologies such as noninvasive prenatal diagnostics, laboratory developed tests, and genetic analysis platforms, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, litigation involving the Company, and other risks detailed from time to time in the Company's most recently filed Quarterly Report on Form 10-Q and Annual Report on Form 10-K for the year ended December 31, 2011, and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

SOURCE Sequenom, Inc.

Sequenom Announces Leadership Appointments

Tue, 11 Dec 2012 07:00:00 -0500

Dec 11, 2012

SAN DIEGO, Dec. 11, 2012 /PRNewswire/ -- Sequenom, Inc. (Nasdaq: SQNM) announced today the appointments of William Welch as the Company's President and Chief Operating Officer and Dirk van den Boom as the Company's Executive Vice President, Research & Development and Chief Technology Officer, both effective immediately. Additionally, Ronald Lindsay has been named as the Company's Executive Vice President, Strategic Planning. Harry F. Hixson, Jr. will continue to serve as Chairman and Chief Executive Officer.

Mr. Welch joined Sequenom in January 2011 as Senior Vice President, Diagnostics. He has overseen the Company's commercial operations in connection with the October 2011 launch of its MaterniT21 PLUS laboratory-developed test.

"Bill's extensive industry experience and knowledge have been a significant asset to Sequenom over the last two years as we launched the MaterniT21 PLUS test," said Harry Hixson, Jr., Chairman and Chief Executive Officer. "This promotion reflects his many contributions to the growth of our company and the board's confidence in his future leadership capacity."

Dr. van den Boom has served as Sequenom's Senior Vice President of research and development since August 2010 and previously served as the Company's vice president, research and development. He joined Sequenom in 1998 at the company's Hamburg office, subsequently serving in various management roles of increasing responsibility within the R&D department.

"Dirk has demonstrated impressive professional and managerial growth over the past three years and we look forward to his contributions as he takes the helm of R&D leadership at Sequenom," said Ronald M Lindsay, Director and newly appointed EVP of Strategic Planning. "We believe Dirk will successfully drive key strategic initiatives that will underpin the company's future growth."

Dr. Lindsay has served as Sequenom's Executive Vice President, Research & Development since August 2010 and previously served as interim Senior Vice President, Research and Development. Dr. Lindsay has served as a member of Sequenom's Board of Directors since 2003.

Prior to joining Sequenom, Mr. Welch was a consultant to molecular diagnostic companies in the personalized medicine sector. From August 2005 to September 2009, Mr. Welch was senior vice president and chief commercial officer at Monogram Biosciences, a bioscience laboratory services company. Prior to his time at Monogram, Mr. Welch was vice president of sales and marketing at La Jolla Pharmaceuticals and vice president of global marketing with Dade Behring MicroScan. Mr. Welch entered the healthcare field with Abbott Laboratories where he held progressive management positions, including General Manager. Mr. Welch earned a B.S. with honors in chemical engineering from the University of California at Berkeley and received his M.B.A. from Harvard University.

Dr. van den Boom received his Ph.D. in Biochemistry/Molecular Biology from the University of Hamburg where he focused on various aspects of nucleic acid analysis with mass spectrometry. He has co-authored more than 50 scientific articles and is an inventor on 48 patents or patent applications.

About Sequenom

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the Company's expectations regarding future leadership and contributions, the Company's future growth, and the Company's commitment to improving healthcare through revolutionary genetic analysis solutions, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market demand for and acceptance and use of technology and tests such as the MaterniT21 PLUS test, reliance upon the collaborative efforts of other parties including without limitation any international distributors or licensees, the Company or third parties obtaining or maintaining regulatory approvals that impact the Company's business, government regulation particularly with respect to diagnostic products and laboratory developed tests, publication processes, the performance of designed product enhancements, the Company's ability to develop and commercialize technologies and products, particularly new technologies such as noninvasive prenatal diagnostics, laboratory developed tests, and genetic analysis platforms, the Company's financial position, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, litigation involving the Company, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission, including without limitation its Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 and its Annual Report on Form 10-K for the year ended December 31, 2011. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

SOURCE Sequenom, Inc.

Sequenom, Inc. Announces Issuance Of Patent For Methods Of Detecting Fetal Aneuploidy

Thu, 06 Dec 2012 16:05:00 -0500

Dec 6, 2012

SAN DIEGO, Dec. 6, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced that the U.S. Patent and Trademark Office will issue U.S. Patent No. 8,340,916 on December 25, 2012 with claims to novel methods for detecting fetal aneuploidy using massively parallel sequencing. The patent is entitled Diagnosing Fetal Chromosomal Aneuploidy Using Massively Parallel Genomic Sequencing and was invented by Drs. Dennis Lo, Rossa Chiu and Alan Chan of the Chinese University of Hong Kong. Sequenom has exclusive rights to this patent.

About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the Company's commitment to improving healthcare through revolutionary genetic analysis solutions, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market demand for and acceptance and use by customers of its products, reliance upon the collaborative efforts of other parties, the Company's financial position, its ability to position itself for product launches and growth and develop and commercialize new technologies and products, particularly newer technologies such as noninvasive prenatal diagnostics, laboratory developed tests, and genetic analysis platforms, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, litigation involving the Company, and other risks detailed from time to time in the Company's most recently filed Quarterly Report on Form 10-Q and Annual Report on Form 10-K for the year ended December 31, 2011, and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

SOURCE Sequenom, Inc.

Sequenom Announces Participation at Oppenheimer 23rd Annual Healthcare Conference

Thu, 06 Dec 2012 07:00:00 -0500

Dec 6, 2012

SAN DIEGO, Dec. 6, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced the Company's participation at the upcoming Oppenheimer 23^rd Annual Healthcare Conference, to be hosted at the Waldorf Astoria in New York, NY.

On Thursday, December 13, Ronald M. Lindsay, Ph.D., Director and EVP of Research and Development and Paul V. Maier, Chief Financial Officer, will present starting at 10:00 am ET to provide an overview of and update on the Company.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

SOURCE Sequenom, Inc.

The American College of Obstetricians and Gynecologists Committee on Genetics and the Society for Maternal-Fetal Medicine Publications Committee Recommend Noninvasive Prenatal Testing for Fetal Aneuploidy

Wed, 21 Nov 2012 07:00:00 -0500

Nov 21, 2012

SAN DIEGO, Nov. 21, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced that the American College of Obstetricians and Gynecologists (ACOG) Committee on Genetics and the Society for Maternal-Fetal Medicine (SMFM) Publications Committee issued a joint Committee Opinion on November 20, 2012, recommending that cell-free fetal DNA testing be offered to patients at increased risk of aneuploidy. It can also be used as a follow-up test for women with a positive first-trimester or second-trimester screening test result.

Previously, the ACOG recommended that women, regardless of maternal age, be offered prenatal assessment for aneuploidy by screening or invasive prenatal diagnosis. The ACOG Committee on Genetics and the SMFM Publications Committee now recommend that women at increased risk of aneuploidy be offered cell-free fetal DNA as an option that can be used as a primary screening test based on the following indications:

Maternal age 35 years or older at delivery.
Fetal sonographic findings indicating an increased risk of aneuploidy.
History of a prior pregnancy with a trisomy.
Positive test result for aneuploidy, including first trimester, sequential, or integrated screen, or a quadruple screen.
Parental balanced robertsonian translocation with increased risk for fetal trisomy 13 or 21.

The Committee Opinion also recommended that "cell-free fetal DNA testing should not be offered to low-risk women or women with multiple gestations because it has not been sufficiently evaluated in these groups." Further, the Committee Opinion stated that "pre-test counseling should be an informed patient choice after pre-test counseling and should not be part of routine prenatal laboratory assessment. A patient with a positive test result should be referred for genetic counseling and offered invasive prenatal diagnosis for confirmation of test results."

"The issuance of the ACOG/SMFM opinion on the use of cell-free fetal DNA testing represents a major step forward for the integration of this valuable technology into pregnancy care programs" said Allan Bombard, MD, Sequenom's Chief Medical Officer. "We fully support the indications for considering the use of cell-free fetal DNA outlined in the Committee Opinion and believe this will be a valuable tool to help guide physicians and their patients in the most appropriate prenatal care."

ACOG is the nation's leading group of physicians providing health care for women. The College strongly advocates for quality health care for women, maintains the highest standards of clinical practice and continuing education of its members, promotes patient education, and increases awareness among its members and the public of the changing issues facing women's health care.

SMFM is a non-profit membership group for obstetricians/gynecologists who have additional formal education and training in maternal-fetal medicine. The society is devoted to reducing high-risk pregnancy complications by providing continuing education to its 2,000 members on the latest pregnancy assessment and treatment methods. It also serves as an advocate for improving public policy, and expanding research funding and opportunities for maternal-fetal medicine.

The full text of the Committee Opinion can be found at: Noninvasive prenatal testing for fetal aneuploidy. Committee Opinion No. 545. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012: 120:1532-4.

About the MaterniT21 PLUS Test

The MaterniT21 PLUS test analyzes the relative amount of 21, 18, 13 and Y chromosomal material in cell-free DNA. The test is intended for use in pregnant women at increased risk for fetal aneuploidy and can be used as early as 10 weeks gestation. Estimates suggest there are about 750,000 pregnancies at high risk for fetal aneuploidy each year in the United States. The MaterniT21 PLUS test is available exclusively through the Sequenom Center for Molecular Medicine (Sequenom CMM) as a testing service provided to physicians. To learn more about the test, please visit www.Sequenomcmm.com.

About Sequenom

Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

Sequenom CMM, LLC

Sequenom Center for Molecular Medicine® (Sequenom CMM), a CAP accredited and CLIA-certified molecular diagnostics laboratory, is developing a broad range of laboratory developed tests with a focus on prenatal and ophthalmic diseases and conditions. These laboratory-developed tests provide beneficial patient management options for obstetricians, geneticists and maternal fetal medicine specialists, and retinal specialists. Sequenom CMM is changing the landscape in genetic disorder diagnostics using proprietary cutting edge technologies.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the integration of cell-free fetal DNA testing into pregnancy care programs, the expected impact and benefits of the new guidelines on physicians and patients, and Sequenom CMM changing the landscape in genetic disorder diagnostics using proprietary cutting edge technologies, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market demand for and acceptance and use of technology and tests such as the MaterniT21 PLUS test, reliance upon the collaborative efforts of other parties including without limitation any international distributors or licensees, the Company or third parties obtaining or maintaining regulatory approvals that impact the Company's business, government regulation particularly with respect to diagnostic products and laboratory developed tests, publication processes, the performance of designed product enhancements, the Company's ability to develop and commercialize technologies and products, particularly new technologies such as noninvasive prenatal diagnostics, laboratory developed tests, and genetic analysis platforms, the Company's financial position, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, litigation involving the Company, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission, including without limitation its Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 and its Annual Report on Form 10-K for the year ended December 31, 2011. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

SOURCE Sequenom, Inc.

Study Shows Sequenom CMM's RetnaGene LDT Accurately Predicts Risk of Progression to Wet Form of AMD

Mon, 12 Nov 2012 16:50:00 -0500

Results Evaluating Genetic Test Presented at AAO Annual Meeting

Nov 12, 2012

SAN DIEGO, Nov. 12, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced its wholly-owned subsidiary, Sequenom Center for Molecular Medicine (Sequenom CMM), presented results from a study of its RetnaGene AMD laboratory-developed test to predict risk of disease progression during the 2012 Joint Meeting of the American Academy of Ophthalmology and the Asia-Pacific Academy of Ophthalmology in Chicago.

This Sequenom CMM laboratory-developed genetic test (LDT) combines patient disease stage with patient genetic variation to evaluate the risk of a patient with early or intermediate AMD to progress to advanced choroidal neovascularization (CNV) disease within 2, 5, and 10 years. CNV is the most common form of 'wet' advanced age-related macular degeneration (AMD), in which new blood vessels in the eye leak fluid, compromising central vision. Advanced disease impacts approximately 10 percent of AMD patients, but is associated with 90 percent of vision loss in AMD.

The clinical validation of the laboratory test predicting progression to CNV was conducted using patient DNA samples made available through the National Eye Institute's Age-Related Eye Disease Study (AREDS). More than 2,000 patients were genotyped for 13 single nucleotide gene polymorphisms (SNPs) in genes previously shown to be associated with CNV. Sequenom CMM compared the predictive value of a phenotype model, based on the assessment of disease grade currently used in clinical practice. The predictive model that combined genotype with phenotype was found to be more accurate in predicting CNV progression (AUC=0.96) than the phenotype model alone based on disease grade (AUC=0.89), concluding that inclusion of the genotype assessment is more effective in predicting CNV progression compared with phenotype alone.

"Physicians today rely on an assessment of patient disease stage to predict the risk of progressing to CNV, and this genetic laboratory developed test will help improve the accuracy of prediction by assessing individual risk based on the genetic predisposition of the patient," said Allan T. Bombard, M.D., Sequenom's Chief Medical Officer.

The study was conducted in compliance with the Coriell Cell Repositories Institutional Review Board, in accordance with Department of Health and Human Services (45 CFR Part 46). The dataset used for the analysis was obtained from the National Eye Institute-Age-Related Eye Disease Study (NEI-AREDS) Genetic Repository. Funding support for AREDS was provided by the National Eye Institute grant N01-EY-0-2127, National Institutes of Health, Bethesda, Maryland.

At the meeting: Paper 30031594: Combining Genotype and Phenotype to Predict Progression to Choroidal Neovascularization (CNV) in Patients with AMD (Presented Monday, November 12, 3:42 PM in S406B)

Sequenom CMM, LLC
Sequenom Center for Molecular Medicine® (Sequenom CMM), a CAP accredited and CLIA-certified molecular diagnostics laboratory, is developing a broad range of laboratory-developed tests with a focus on prenatal and ophthalmic diseases and conditions. These laboratory-developed tests provide beneficial patient management options for obstetricians, geneticists, maternal fetal medicine specialists, retinal specialists and ophthalmologists. Sequenom CMM is changing the landscape in genetic disorder diagnostics using proprietary cutting edge technologies.

Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding the benefits or expectations of Sequenom CMM's genetic AMD test including the test's ability to help improve the accuracy of predicting the risk of a patient progressing to CNV by assessing individual risk based on the genetic predisposition of the patient, Sequenom's commitment to improving healthcare through revolutionary genetic analysis solutions, and Sequenom CMM changing the landscape in genetic disorder diagnostics. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with Sequenom's ability to develop and commercialize new technologies and products and to scale up its operations to meet increased product demand, particularly for new technologies and products such as Sequenom CMM's prenatal and other diagnostics testing services, Sequenom's ability to manage its existing cash resources or raise additional cash resources, customer demand, Sequenom's ability to obtain payor reimbursement and payment collection and the timing thereof, for Sequenom CMM's diagnostic test services including the MaterniT21 PLUS LDT, Sequenom's ability to convert to accrual accounting for its diagnostic test services including the MaterniT21 PLUS LDT, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, ongoing litigation, including patent litigation asserting infringement by our products or challenging the validity of our patents, and other risks detailed from time to time in Sequenom, Inc.'s most recent Quarterly Report on Securities and Exchange Commission Form 10-Q and Annual Report on Securities and Exchange Commission Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Sequenom, Inc. undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

SOURCE Sequenom, Inc.

Sequenom, Inc. Reports Financial Results For The Third Quarter Of 2012 And Announces 90,000 Annualized Run Rate For MaterniT21™ PLUS Tests

Thu, 08 Nov 2012 16:05:00 -0500

Forty-Six Million Lives Now Under Coverage For Sequenom CMM MaterniT21™ PLUS Test

Nov 8, 2012

SAN DIEGO, Nov. 8, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today reported revenue of $22.9 million for the third quarter of 2012, an increase of 25% from revenue of $18.3 million in the second quarter of 2012 and a 68% increase compared to revenue of $13.6 million for the third quarter of 2011. Revenues from the Sequenom Center for Molecular Medicine (Sequenom CMM) diagnostic testing services operating segment grew to $12.5 million in the third quarter of 2012, while revenues from the genetic analysis operating segment were $10.4 million in the third quarter of 2012.

Also during the third quarter of 2012, Sequenom CMM established a number of new agreements with networks and insurance providers, increasing the number of lives covered with in-network access to the MaterniT21 PLUS laboratory developed test (LDT) from 26 million to 46 million.

"The results from this quarter illustrate the impact of the Company's strategic approach, as we have focused on maintaining our leadership position within our markets," said Harry Hixson, Jr., Ph.D., Chairman and CEO of Sequenom. "Overall, the last year has been an exciting time as Sequenom CMM introduced the MaterniT21 PLUS LDT and dramatically scaled up operations to support the overwhelming response from the obstetrics and maternal-fetal medicine physician community. We are pleased that Sequenom CMM has reached a 90,000 annualized test volume run rate for the MaterniT21 PLUS test. We will also continue to seek new molecular diagnostic growth opportunities as we move into 2013."

Diagnostic services revenue is primarily recognized when cash is received, while costs are recognized in the current period upon completion of the services. The costs associated with increasing test volumes resulted in decreased gross margins as the Company has not yet recognized revenue related to the increased number of laboratory tests performed, which have been billed but not yet collected.

Gross margin in the third quarter of 2012 was 26% of revenues as compared to a gross margin of 60% in the same period one year ago, a difference primarily attributable to current cash accounting for diagnostics revenue and higher test volumes, a result of the growing market adoption of the Sequenom CMM MaterniT21 PLUS LDT. Gross margin is expected to continue to fluctuate quarterly due to changes in sales volumes and the timing of cash receipts until the Company converts to accrual accounting for diagnostic services revenue, which is expected to occur after sufficient reimbursement history has been established.

Total operating expenses for the third quarter of 2012 were $35.7 million, as compared to total expenses of $26.4 million for the third quarter of 2011. This change primarily reflects a 49% increase in selling and marketing expense resulting from higher labor costs associated with additional headcount to increase market penetration and support the continued expansion of the diagnostic services market, including sales force expansion during the third quarter.

General and administrative expenses increased in the third quarter of 2012 to $10.1 million as compared to $5.5 million in the same period one year ago. The increase was due primarily to higher legal costs associated with patent litigation, and higher labor costs associated with additional headcount to support operations. Total stock-based compensation expense was $3.1 million for the third quarter of 2012, flat as compared to the third quarter of 2011.

Net loss for the third quarter of 2012 grew to $30.2 million, or $0.26 per share, resulting from an increase in costs associated primarily with the growth in testing volume of the MaterniT21 PLUS LDT. This compares to a net loss of $18.4 million, or $0.19 per share for the same period in 2011.

"We are pleased with the continuing ramp up of our diagnostic services revenue, driven primarily by the rapid adoption of Sequenom CMM MaterniT21 PLUS LDT. Importantly, we are seeing greater recognition from the payors and networks as 46 million Americans now have network access to the test," said Paul V. Maier, Sequenom's CFO. "Additionally, to support our continued growth, we strengthened our balance sheet significantly with the completion of our $130 million convertible note financing transaction in September of 2012."

Year-To-Date Results
For the first nine months of 2012, the Company reported revenue of $56.0 million, an increase of 39% from revenue of $40.4 million for the first nine months of 2011. Revenues in the first nine months of 2012 from the Sequenom CMM diagnostics services operating segment grew to $25.4 million, while revenues from the genetic analysis operating segment were $30.6 million in the first nine months of 2012.

Gross margin for the first nine months of 2012 was 31% of revenue as compared to gross margin of 63% for the first nine months of 2011. Total operating expenses for the first nine months of 2012 were $100.6 million, as compared to total expenses of $77.8 million for the first nine months of 2011.

Net loss for the first nine months of 2012 was $84.3 million, or $0.74 per share, as compared to net loss of $52.0 million, or $0.52 per share for the same period in 2011, reflecting an increase in costs associated primarily with the growth in sales volume of the MaterniT21 PLUS LDT.

As of September 30, 2012, total cash, cash equivalents, and marketable securities were $193.4 million. In the third quarter of 2012, the Company completed a private offering of $130.0 million convertible, unsecured, senior notes with the intent to use the net proceeds to fund continued commercialization of the MaterniT21 PLUS LDT, as well as for other general corporate purposes, which may include research and development expenses, capital expenditures, working capital and general administrative expenses.

Net cash used in operating activities was $63.7 million for the first nine months of 2012, while purchases of capital equipment and leasehold improvement for the same period totaled $14.2 million, funded partially through utilization of the Company's credit facility. As of September 30, 2012, the Company had borrowed $20.0 million under the credit facility.

Operational Updates
Sequenom CMM accessioned approximately 26,000 total test samples in the third quarter of 2012, including nearly 18,000 MaterniT21 PLUS test samples. Sequenom CMM celebrated the one-year anniversary of the commercial availability of the MaterniT21 PLUS LDT with a total of approximately 37,000 samples accessioned since the launch in the fall of 2011. At the close of October 2012, the annualized run rate of MaterniT21 PLUS samples accessioned was more than 90,000 test samples, an average of more than 1,700 samples weekly. Sequenom CMM now expects to significantly exceed its previously announced internal goal of 50,000 MaterniT21 PLUS tests billed for 2012.

Additionally, The Blue Cross and Blue Shield Association Medical Advisory Panel announced completion of their technology assessment, concluding nucleic acid sequencing-based testing of maternal plasma for fetal trisomy 21 with confirmatory testing of positive results in both high-risk women and average-risk women being screened for fetal trisomy 21 meets the Blue Cross and Blue Shield Association Technology Evaluation Center (TEC) criteria.

The California Technology Assessment Forum (CTAF) also completed an independent evaluation of the cell-free fetal DNA technology used in the Sequenom CMM MaterniT21 PLUS LDT. The CTAF recommended that the use of cell free fetal DNA as a prenatal advanced screening test for fetal aneuploidy for Trisomy 21 and Trisomy 18 in high risk women meets all five of the CTAF criteria for safety and efficacy and improvement in health outcomes. Blue Shield of California Foundation (BSCF) spearheads the CTAF, which was established to assess new and emerging medical technology.

On November 2, 2012 the U.S. Patent & Trademark Office issued a Notice of Allowance for a U.S. patent covering novel methods for the use of massively parallel sequencing to detect fetal aneuploidies, such as Trisomy 21. Sequenom has licensed the exclusive rights to the invention, which was made by Drs. Dennis Lo, Rossa Chiu and Alan Chan of the Chinese University of Hong Kong ("CUHK"). The Notice of Allowance was issued in connection with U.S. patent application no. 12/178,181.

"The allowed patent claims are an important component of Sequenom's prenatal patent strategy and the protection of its business and we look forward to their issuance," continued Harry Hixson, Jr. "When issued, this new patent will be a significant addition to Sequenom's intellectual property portfolio."

The Company also established additional international distribution agreements to expand access to the MaterniT21 PLUS testing service outside the United States. Current agreements now include Japan, Hong Kong, the Czech Republic, Slovakia, the Netherlands and Israel.

In response to sustained growth in commercial interest for the MaterniT21 PLUS testing service, Sequenom CMM increased its sequencing-based test capacity in the third quarter, from 100,000 to more than 200,000 test samples per year. Sequenom CMM has also rapidly expanded access to the testing services for eligible patients, from 20 metropolitan areas at launch to all 50 states, with a significantly augmented sales force of 75 representatives, up from 20 at launch in the fall of 2011.

As of the end of the third quarter, the testing service run rate had reached more than 10 percent of the high risk U.S. market of 750,000 women. Approximately 30 percent of the maternal fetal medical specialists in the United States have ordered the MaterniT21 PLUS test in their practices.

Conference Call Information
A conference call will take place today, November 8, 2012, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) hosted by Chairman and CEO Harry F. Hixson, Jr., Ph.D., and other members of senior management. To access the live teleconference call, dial 800-860-2442 in the U.S., 866-605-3852 in Canada (both are toll free), and 412-858-4600 for other international callers. Please specify to the operator that you would like to join the "Sequenom Third Quarter 2012 Earnings Conference Call." If you are unable to listen to the live webcast, a teleconference replay will be available through Friday, November 23, 2012. Interested parties can access the rebroadcast by dialing 877-344-7529 or 412-317-0088 internationally and entering the conference number 10016291.

About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The Company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

About Sequenom Center for Molecular Medicine
Sequenom Center for Molecular Medicine (Sequenom CMM^®) is a CAP accredited and CLIA-certified molecular diagnostics reference laboratory with facilities in San Diego, CA and Grand Rapids, MI. Sequenom CMM is dedicated to the development and commercialization of laboratory developed tests for prenatal and retinal conditions and diseases. Utilizing innovative proprietary technologies, Sequenom CMM provides test results that can be used as tools by clinicians in managing patient care. Testing services are available only upon request to physicians. Sequenom CMM works closely with key opinion leaders and experts in obstetrics, retinal care and genetics. Sequenom CMM scientists use a variety of sophisticated and cutting-edge methodologies in the development and validation of tests. Sequenom CMM is changing the landscape in genetic diagnostics. Visit http://www.scmmlab.com for more information on laboratory testing services.

SEQUENOM^®, Sequenom CMM^®, MaterniT21™ and MaterniT21™ PLUS are trademarks of Sequenom. All other trademarks and service marks are the property of their respective owners.

Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding Sequenom's full-year MaterniT21 PLUS test volume goal of 50,000 tests billed for 2012, and expectations of significantly exceeding this goal, plans to seek new molecular diagnostic growth opportunities, expected continued quarterly fluctuations in gross margin, efforts to increase market penetration of diagnostic services, plans for continued growth, including international distribution agreements, strategies to expand the reach of Sequenom CMM's testing services, annualized sample accession run rates for the MaterniT21 PLUS LDT, growing commercial interest and demand for Sequenom CMM's testing services and Sequenom CMM's efforts to further expand its prenatal sales force during the second half of 2012, Sequenom's commitment to improving healthcare through revolutionary genetic analysis solutions, Sequenom CMM's dedication to the development and commercialization of laboratory developed tests, and changing the landscape in genetic diagnostics, and Sequenom's expectations with respect to the issuance of patents. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with Sequenom's ability to develop and commercialize new technologies and products and to scale up its operations to meet increased product demand, particularly for new technologies and products such as Sequenom CMM's prenatal and other diagnostics testing services, Sequenom's ability to manage its existing cash resources or raise additional cash resources, customer demand for and Sequenom's ability to obtain payor reimbursement and payment collection and the timing thereof, for Sequenom CMM's diagnostic test services including the MaterniT21 PLUS LDT, Sequenom's ability to convert to accrual accounting for its diagnostic test services including the MaterniT21 PLUS LDT, competition, intellectual property protection and intellectual property rights of others, government regulation particularly with respect to diagnostic products and laboratory developed tests, obtaining or maintaining regulatory approvals, ongoing litigation, including patent litigation asserting infringement by our products or challenging the validity of our patents, and other risks detailed from time to time in Sequenom, Inc.'s most recent Quarterly Report on Securities and Exchange Commission Form 10-Q and Annual Report on Securities and Exchange Commission Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and Sequenom, Inc. undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

[Financial tables follow]

SEQUENOM, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS *(in thousands, except per share data)*

	Three months ended		Nine months ended
	September 30,		September 30,
	2012	2011	2012	2011
Revenues:
Genetic analysis product sales and services	$ 10,352	$ 11,362	$ 30,633	$ 34,929
Diagnostic services	12,501	2,219	25,392	5,494
Total revenues	22,853	13,581	56,025	40,423

Costs and expenses:
Cost of genetic analysis product sales and services	3,010	3,501	8,581	10,274
Cost of diagnostic services	13,836	1,958	30,114	4,714
Total cost of revenues	16,846	5,459	38,695	14,988
Gross Margin	6,007	8,122	17,330	25,435

Selling and marketing	12,358	8,276	33,418	22,014
Research and development	13,243	12,643	39,776	40,420
General and administrative	10,126	5,461	27,425	15,337
Total operating expenses	35,727	26,380	100,619	77,771

Loss from operations	(29,720)	(18,258)	(83,289)	(52,336)

Other (expense) income, net	(486)	(24)	(970)	409
Loss before income taxes	(30,206)	(18,282)	(84,259)	(51,927)
Income tax expense	(20)	(90)	(42)	(53)
Net loss	(30,226)	(18,372)	(84,301)	(51,980)

Net loss per share, basic and diluted	$ (0.26)	$ (0.19)	$ (0.74)	$ (0.52)

Comprehensive loss	$ (30,071)	$ (18,612)	$ (84,304)	$ (51,781)

Weighted-average shares outstanding, basic and diluted	114,712	99,220	113,263	99,082

SEQUENOM, INC. UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS *(in thousands)*

	September 30,	December 31,
	2012	2011
Assets:
Cash, cash equivalents, marketable securities	$ 193,388	$ 84,216
Restricted cash	162	66
Accounts receivable, net	8,095	6,972
Inventories	11,966	8,729
Other current assets and prepaid expenses	4,102	3,533
Total current assets	217,713	103,516

Equipment and leasehold improvements, net	29,298	19,629
Other assets	17,177	12,402
Total assets	$ 264,188	$ 135,547

Liabilities and Stockholders' Equity:
Accounts payable	$ 13,971	$ 8,435
Accrued expenses and other current liabilities	18,750	16,530
Deferred revenue	1,942	2,137
Note payable, current portion	7,568	1,902
Total current liabilities	42,231	29,004

Long-term liabilities	146,370	15,155
Stockholders' equity	75,587	91,388
Total liabilities and stockholders' equity	$ 264,188	$ 135,547

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

SOURCE Sequenom, Inc.

Sequenom Announces Participation At Two Upcoming Investor Conferences

Tue, 06 Nov 2012 16:00:00 -0500

Nov 6, 2012

SAN DIEGO, Nov. 6, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced the Company's participation at the upcoming Lazard Capital Markets 9^th Annual Healthcare Conference in New York and the Jefferies 2012 Global Healthcare Conference in London.

On Tuesday, November 13, Harry F. Hixson Jr., Ph.D., Sequenom's Chief Executive Officer, will present at the Lazard Capital Markets 9^th Annual Healthcare Conference, starting at 9:30 am ET to provide an overview of and update on the Company. Then, on Thursday, November 15, Dr. Hixson will present at the Jefferies 2012 Global Healthcare Conference, starting at 2:20 pm GMT.

Both presentations are expected to last approximately 30 minutes and will be webcast live through the "Investors" section of the Sequenom website at www.sequenom.com. Audio replays will be available for 30 days following the initial presentation webcasts.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

SOURCE Sequenom, Inc.

California Technology Assessment Forum Recommends Use Of Cell-Free DNA Technology As Advanced Prenatal Testing For Pregnant Women At High Risk For Fetal Chromosomal Anomalies

Thu, 18 Oct 2012 16:00:00 -0400

Oct 18, 2012

SAN DIEGO, Oct. 18, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced that the California Technology Assessment Forum completed an independent evaluation of the cell-free fetal DNA technology used in the Sequenom Center for Molecular Medicine's (Sequenom CMM) MaterniT21 PLUS™ laboratory-developed test (LDT). CTAF recommended that the use of cell-free fetal DNA as a prenatal advanced screening test for fetal aneuploidy for Trisomy 21 and Trisomy 18 in high risk women meets all five CTAF criteria for safety and efficacy and improvement in health outcomes.

Blue Shield of California Foundation (BSCF) spearheads the California Technology Assessment Forum (CTAF), which was established to assess new and emerging medical technology. CTAF is one of the preeminent independent medical technology assessment organizations in the country. A multidisciplinary group of medical providers, researchers, ethicists, and consumer advocates work to discuss and formulate positions on the safety and effectiveness of new and emerging technologies. Approximately 15 new technologies are reviewed each year, including devices, procedures and diagnostics.

CTAF uses the following criteria in its assessment process: 1) the technology must have final approval from the appropriate government regulatory bodies; 2) the scientific evidence must permit conclusions concerning the effectiveness of the technology regarding health outcomes; 3) the technology must improve net health outcomes; 4) the technology must be as beneficial as any established alternative(s); and 5) the improvement must be attainable outside the investigational setting.

"We are very pleased with the recommendation from CTAF. As one of the leading independent organizations in the biomedical field, CTAF recommendations support the broadened acceptance of novel technologies into clinical practice. We see it as further assurance for physicians and patients of the safety and efficacy of this non-invasive approach to detect fetal aneuploidies in appropriate high risk groups," said Bill Welch, Senior Vice President, Diagnostics at Sequenom.

The following CTAF recommendations were unanimously approved at the October 17 review meeting:

It is recommended that the use of cell-free fetal DNA as a prenatal advanced screening test for fetal aneuploidy for Trisomy 21 and Trisomy 18 in high risk women meets all five CTAF criteria for safety and efficacy and improvement in health outcomes.
It is recommended that the use of cell-free fetal DNA as a prenatal advanced screening test for fetal aneuploidy for Trisomy 13 in high risk women does not meet CTAF criteria 4-5 for safety and efficacy and improvement in health outcomes.
It is recommended that the use of cell-free fetal DNA as a prenatal primary screening test for fetal aneuploidy for Trisomy 21, Trisomy 18, and Trisomy 13 in average and high risk women does not meet CTAF criteria 3 through 5 for safety and efficacy and improvement in health outcomes.

The MaterniT21 PLUS test is intended for use in pregnant women at high risk for fetal aneuploidy and can be used as early as 10 weeks gestation. Estimates suggest there are about 750,000 pregnancies at high risk for fetal aneuploidy each year in the United States. The test detects an increased amount of chromosomal material for trisomies 21, 18 and 13, as well as fetal gender. The MaterniT21 PLUS test is available exclusively through the Sequenom Center for Molecular Medicine (Sequenom CMM) as a testing service provided to physicians. To learn more about the test, please visit www.Sequenomcmm.com.

About Sequenom
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.

Sequenom CMM, LLC
Sequenom Center for Molecular Medicine® (Sequenom CMM), a CAP accredited and CLIA-certified molecular diagnostics laboratory, is developing a broad range of laboratory developed tests with a focus on prenatal and ophthalmic diseases and conditions. These laboratory-developed tests provide beneficial patient management options for obstetricians, geneticists and maternal fetal medicine specialists, and retinal specialists. Sequenom CMM is changing the landscape in genetic disorder diagnostics using proprietary cutting edge technologies.

Forward-Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding expectations, or the effect or impact of the CTAF recommendations, the Company's commitment to improving healthcare through revolutionary genetic analysis solutions, and Sequenom CMM changing the landscape in genetic disorder diagnostics, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market demand for and acceptance and use of technology and tests such as the MaterniT21 PLUS test, reliance upon the collaborative efforts of other parties including without limitation any international distributors or licensees, the Company or third parties obtaining or maintaining regulatory approvals that impact the Company's business, government regulation particularly with respect to diagnostic products and laboratory developed tests, publication processes, the performance of designed product enhancements, the Company's ability to develop and commercialize technologies and products, particularly new technologies such as noninvasive prenatal diagnostics, laboratory developed tests, and genetic analysis platforms, the Company's financial position, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others, litigation involving the Company, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission, including without limitation its Current Report on Form 8-K filed on September 10, 2012, Quarterly Report on Form 10-Q for the quarter ended June 30, 2012 and its Annual Report on Form 10-K for the year ended December 31, 2011. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

SOURCE Sequenom, Inc.

Sequenom, Inc. Announces Date Of Third Quarter 2012 Financial Results And Conference Call

Mon, 15 Oct 2012 07:00:00 -0400

Oct 15, 2012

SAN DIEGO, Oct. 15, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced it will report financial results for the third quarter of 2012 after closing of the NASDAQ Global Market on Thursday, November 8, 2012.

To access the live teleconference call, dial 800-860-2442 in the U.S., 866-605-3852 in Canada (both are toll free), and 412-858-4600 for other international callers. Please specify to the operator that you would like to join the "Sequenom Third Quarter 2012 Earnings Conference Call." If you are unable to listen to the live webcast, a teleconference replay will be available through Thursday, November 15, 2012. Interested parties can access the replay by dialing 877-344-7529 or 412-317-0088 internationally and entering the conference number 10019497.

About Sequenom Center for Molecular Medicine
Sequenom Center for Molecular Medicine (Sequenom CMM^®) has two CAP accredited and CLIA-certified molecular diagnostics reference laboratories dedicated to the development and commercialization of laboratory developed tests for prenatal and eye conditions and diseases. Utilizing innovative proprietary technologies, Sequenom CMM provides test results that can be used as tools by clinicians in managing patient care. Testing services are available only upon request to physicians. Sequenom CMM works closely with key opinion leaders and experts in obstetrics, retinal care and genetics. Sequenom CMM scientists use a variety of sophisticated and cutting-edge methodologies in the development and validation of tests. Sequenom CMM is changing the landscape in genetic diagnostics. Visit http://www.scmmlab.com for more information on laboratory testing services.

SEQUENOM^®, MaterniT21™ and MaterniT21™ PLUS are trademarks of Sequenom. All other trademarks and service marks are the property of their respective owners.

(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO)

SOURCE Sequenom, Inc.